Haptoglobin genotypes and refractory hypertension in type 2 diabetes mellitus patients

BACKGROUND: It has been suggested that haptoglobin polymorphism may influence the pathogenesis of microvascular and macrovascular complications in diabetic patients. OBJECTIVE: This cross sectional study was carried out to investigate the existence or not of an association between haptoglobin genotypes and prevalence of ischemic cardiovascular events (stable angina, unstable angina and acute myocardial infarction), systemic arterial hypertension, refractory hypertension, obesity and dyslipidemia in 120 type-2 diabetes mellitus patients followed up at Hospital de Clínicas da UNICAMP in Campinas, São Paulo state, southeastern Brazil. METHODS: Haptoglobin genotyping was performed by allele-specific polymerase chain reactions. The frequencies of the haptoglobin genotypes were compared with the presence/absence of cardiovascular disease, systemic arterial hypertension, refractory hypertension, obesity and dyslipidemia; systolic and diastolic blood pressure measurements; plasma levels of glucose, cholesterol (total, high density lipoprotein-HDL and low density lipoprotein-LDL) and triglycerides; and serum creatinine levels. RESULTS: Although no association between haptoglobin genotype and the presence of cardiovascular disease could be identified, we found a significant excess of patients with Hp2-1 genotype among those with refractory hypertension, who also had higher systolic and diastolic blood pressure, and total and LDL cholesterol levels. CONCLUSION: Our results suggest that type-2 diabetes mellitus patients with the Hp2-1 genotype may have higher chances of developing refractory hypertension. Further studies in other diabetic populations are required to confirm these findings.FUNDAMENTO: Tem sido sugerido que o polimorfismo da haptoglobina pode influenciar na patogênese das complicações microvasculares e macrovasculares em pacientes diabéticos. OBJETIVO: O objetivo principal deste estudo transversal foi de realizar uma investigação da existência ou não de uma associação entre os genótipos de haptoglobina e a prevalência de eventos isquêmicos cardiovasculares (angina estável, angina instável e infarto agudo do miocárdio), hipertensão arterial sistêmica, hipertensão refratária, obesidade e dislipidemia em 120 pacientes com diabete melito tipo 2, seguidos no Hospital Universitário da Unicamp, em Campinas, Estado de São Paulo. MÉTODOS: A genotipagem da haptoglobina foi realizada por reações em cadeia da polimerase alelo-específicas. As frequências dos genótipos de haptoglobina foram comparadas com a presença/ausência de doença cardiovascular, hipertensão arterial sistêmica, hipertensão refratária, obesidade e dislipidemia; medições de pressão arterial sistólica e diastólica; glicemia, colesterol (total, lipoproteínas de alta densidade - HDL e lipoproteínas de baixa densidade - LDL) e triglicerídeos; assim como níveis de creatinina sérica. RESULTADOS: Embora nenhuma associação entre o genótipo de haptoglobina e a presença de doença cardiovascular tenha sido identificada, encontramos um excesso significativo de pacientes com o genótipo Hp2-1 entre as pessoas com hipertensão refratária, que também apresentavam uma maior pressão arterial sistólica e diastólica e níveis de colesterol total e LDL. CONCLUSÃO: Nossos resultados sugerem que os pacientes com diabete melito tipo 2 com o genótipo Hp2-1 podem apresentar uma maior chance de desenvolver hipertensão refratária. Estudos adicionais em populações diabéticas são necessários para confirmar esses achados.33834

Haptoglobin Genotypes And Refractory Hypertension In Type 2 Diabetes Mellitus Patients.

It has been suggested that haptoglobin polymorphism may influence the pathogenesis of microvascular and macrovascular complications in diabetic patients. This cross sectional study was carried out to investigate the existence or not of an association between haptoglobin genotypes and prevalence of ischemic cardiovascular events (stable angina, unstable angina and acute myocardial infarction), systemic arterial hypertension, refractory hypertension, obesity and dyslipidemia in 120 type-2 diabetes mellitus patients followed up at Hospital de Clínicas da UNICAMP in Campinas, São Paulo state, southeastern Brazil. Haptoglobin genotyping was performed by allele-specific polymerase chain reactions. The frequencies of the haptoglobin genotypes were compared with the presence/absence of cardiovascular disease, systemic arterial hypertension, refractory hypertension, obesity and dyslipidemia; systolic and diastolic blood pressure measurements; plasma levels of glucose, cholesterol (total, high density lipoprotein-HDL and low density lipoprotein-LDL) and triglycerides; and serum creatinine levels. Although no association between haptoglobin genotype and the presence of cardiovascular disease could be identified, we found a significant excess of patients with Hp2-1 genotype among those with refractory hypertension, who also had higher systolic and diastolic blood pressure, and total and LDL cholesterol levels. Our results suggest that type-2 diabetes mellitus patients with the Hp2-1 genotype may have higher chances of developing refractory hypertension. Further studies in other diabetic populations are required to confirm these findings.97338-4

Extreme precipitation-streamflow event in the river Araguari basin, Amapá / Brazil

O objetivo da investigação foi analisar vazões extremas ocorridas entre 9 e 14 de abril de 2011 na bacia do Rio Araguari-AP. A metodologia consistiu de três etapas principais: 1) re-análise da precipitação estimada pelo Modelo BRAMS (Brazilian in Development Regional Atmospheric Model System),utilizando como suporte a sinótica do mesmo período; 2) análise de vazão nas seções de monitoramento hidrológico em Porto Platon, Capivara e Serra do Navio (ADCP-Accustic Doppler Profiller Current); 3) análise estatística da série histórica de vazões máximas em Porto Platon utilizando distribuição de Gumbel. Observou-se que o modelo BRAMS capturou parcialmente o padrão do sistema de precipitação quando comparado com a análise sinótica e com os dados da literatura, mas demandando ainda otimização na representação de respostas hidrológicas extremas. Em Porto Platon foi registrada uma vazão recorde de 4036 m3/s, cujo comportamento foi analisado sob a ótica dos mecanismos disponíveis de monitoramento no Estado. Concluiu-se que tais eventos extremos são pouco detectáveis e oferecem riscos consideráveis aos usuários da bacia. A previsão de vazão, baseada na série hidrológica disponível, era de 100 anos de retorno, mas as análises revelaram que este período seria de 360 anos, indicando significativa fragilidade do sistema de previsão de eventos extremos no Estado.The objective of this investigation was to analyse the extreme river flows which have occurred between 9 and 14 April 2011 in the Rio Araguari-AP. The methodology consisted of three main steps: 1) re-analysis of precipitation estimated by the BRAMS (Brazilian Development in Regional Atmospheric Model System) model using the synoptic of the same period as support, 2) analysis of streamflow in sections of hydrological monitoring in Porto Platon, Capivari and Serra do Navio (ADCP-Accustic Profiller Doppler Current); 3) statistic analysis of the time series of maximum river flows in Porto Platon using Gumbel distribution. It was observed that the BRAMS system partially captured the standard precipitation when compared with the synoptic analysis and literature data, but the extreme hydrological responses representation still needs an optimization. In Porto Platon a flow record of 4036 m3 /s was recorded, whose behavior was analyzed from the perspective of the available monitoring mechanisms in the State. It was concluded that such extreme events are poorly detectable and offer considerable risks to users of the basin. The stream flow prediction based on available hydrological series was 100 years recurrence, but the analysis have revealed that this period would be 360 years, indicating significant deficiency of the prediction system of extreme events in the State

Transtornos psiquiátricos na infância: diagnóstico precoce, intervenções eficazes e considerações éticas

Reconhecer e abordar precocemente transtornos psiquiátricos na infância é vital, pois cerca de 20% das crianças enfrentam desafios que impactam emocionalmente. Com raízes genéticas evidentes desde o segundo trimestre fetal, a intervenção eficaz pode não apenas melhorar a qualidade de vida imediata, mas também reduzir o risco de complicações psiquiátricas ao longo da vida, exigindo uma gestão completa que leve em conta sintomas, contexto de desenvolvimento, ambiente familiar e estressores externos. Este estudo teve como objetivo investigar estratégias para o diagnóstico precoce, implementação de intervenções eficazes e considerações éticas no manejo de transtornos psiquiátricos na infância. Para o alcance desse propósito, realizou-se uma revisão sistemática da literatura, utilizando as base de dados Scielo, Lilacs e Medline. Com a análise dos resultados, concluiu-se que são indispensáveis avaliações clínicas extensas, aplicação de instrumentos psicométricos validados e investigação de fatores desencadeantes para garantir uma avaliação precisa. A participação ativa dos pais, especialmente na terapia cognitivo-comportamental (TCC), é destacada, assim como a necessidade de estratégias personalizadas de manejo. Além disso, a reflexão ética sobre fatores socioculturais e a consideração da criança como um sujeito de direitos são elementos cruciais para uma abordagem integral e contextualizada no cuidado de transtornos psiquiátricos na infância, visando promover o bem-estar duradouro

Pesca do apaiari, Astronotus ocellatus (Agassiz, 1831), e perfil socioeconômico dos pescadores artesanais de uma região da Amazônia brasileira

The artisanal fishery is an important economic and subsistence activity among traditional populations in the Amazon Region. Therefore, the aim of this study was to characterize the fishery of apaiari, Astronotus ocellatus (Agassiz, 1831), and to present a socioeconomic profile of artisanal fishermen in the region lakes of Pracuúba, Amapá, Brazil. From May to August 2011 interviews were conducted using standardized forms with fishermen selected by "snowball" method and aged above 18 years old. A total of 68 fishing workers were interviewed, of which 55 were men and 13 women. It was possible to observe that fishing workers have a wide knowledge of fishery in the Region, including apaiari fishery, and that social and economic lives of the Pracuúba population depend totally of the artisanal fishery

NEOTROPICAL XENARTHRANS: a data set of occurrence of xenarthran species in the Neotropics

Xenarthrans – anteaters, sloths, and armadillos – have essential functions for ecosystem maintenance, such as insect control and nutrient cycling, playing key roles as ecosystem engineers. Because of habitat loss and fragmentation, hunting pressure, and conflicts with 24 domestic dogs, these species have been threatened locally, regionally, or even across their full distribution ranges. The Neotropics harbor 21 species of armadillos, ten anteaters, and six sloths. Our dataset includes the families Chlamyphoridae (13), Dasypodidae (7), Myrmecophagidae (3), Bradypodidae (4), and Megalonychidae (2). We have no occurrence data on Dasypus pilosus (Dasypodidae). Regarding Cyclopedidae, until recently, only one species was recognized, but new genetic studies have revealed that the group is represented by seven species. In this data-paper, we compiled a total of 42,528 records of 31 species, represented by occurrence and quantitative data, totaling 24,847 unique georeferenced records. The geographic range is from the south of the USA, Mexico, and Caribbean countries at the northern portion of the Neotropics, to its austral distribution in Argentina, Paraguay, Chile, and Uruguay. Regarding anteaters, Myrmecophaga tridactyla has the most records (n=5,941), and Cyclopes sp. has the fewest (n=240). The armadillo species with the most data is Dasypus novemcinctus (n=11,588), and the least recorded for Calyptophractus retusus (n=33). With regards to sloth species, Bradypus variegatus has the most records (n=962), and Bradypus pygmaeus has the fewest (n=12). Our main objective with Neotropical Xenarthrans is to make occurrence and quantitative data available to facilitate more ecological research, particularly if we integrate the xenarthran data with other datasets of Neotropical Series which will become available very soon (i.e. Neotropical Carnivores, Neotropical Invasive Mammals, and Neotropical Hunters and Dogs). Therefore, studies on trophic cascades, hunting pressure, habitat loss, fragmentation effects, species invasion, and climate change effects will be possible with the Neotropical Xenarthrans dataset

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials